Abstract
The discovery of fibroblast growth factor 23 (FGF23) has provided a more complete understanding of the regulation of phosphate and mineral homeostasis in health and in chronic kidney disease. It has also offered new insights into stratification of risk of cardiovascular events and death among patients with chronic kidney disease and the general population. In this review, we provide an overview of FGF23 biology and physiology, summarize clinical outcomes that have been associated with FGF23, discuss potential mechanisms for these observations and their public health implications, and explore clinical and population health interventions that aim to reduce FGF23 levels and improve public health.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 247-268 |
| Number of pages | 22 |
| Journal | Annual Review of Nutrition |
| Volume | 37 |
| DOIs | |
| State | Published - Aug 21 2017 |
Funding
This work was supported in part by a grant from the American Heart Association (15SFDRN25080331). Dr. Wolf has served as a consultant or received honoraria from Amag, Amgen, Ardelyx, DiaSorin, Incyte, Keryx, Lilly, Pfizer, Sanofi, Ultragenyx, and ZS Pharma, and received grant support from Shire.
Keywords
- Cardiovascular disease
- Chronic kidney disease
- Fibroblast growth factor 23
- Nutritional metabolism
- Phosphate
ASJC Scopus subject areas
- Nutrition and Dietetics
- Medicine (miscellaneous)
